Healthcare | June 24, 2025
Biocon Biologics collaborates with National Cancer Society Malaysia
The program will start with providing bTrastuzumab to cancer patients facing treatment delays due to budget constraints
The program will start with providing bTrastuzumab to cancer patients facing treatment delays due to budget constraints
WINREVAIR significantly reduced the risk of clinical worsening events in recently diagnosed PAH patients over 70 percent of whom were on double background therapy
The company will provide the necessary response to USFDA within stipulated 15 days
Bonthapally facility is one of the world's largest single-site Paracetamol API manufacturing plants by volume
This is the second and final phase of the overall capacity addition of ?195 kL which was under construction at Unit IV Bidar facility
The transaction is expected to close in Q2 FY 2026
TEMPLE, a Phase 3 multicenter, randomized, double-blind, head-to-head study, evaluated the tolerability, safety and efficacy of atogepant compared to topiramate for the preventive treatment of migraine in adult patients with a history of four or more migraine days per month
The proceeds from the QIP will be utiized for purchase of outstanding optionally convertible debentures
BRAVE study will explore the potential of omaveloxolone to address the critical unmet need of the pediatric FA population
The company received seven observations in the Form-483
Subscribe To Our Newsletter & Stay Updated
